EMEA-003187-PIP01-22 - paediatric investigation plan

Flortaucipir F18

Key facts

• Active Substance:
  Flortaucipir F18
• Therapeutic area:
  Neurology
• Decision number:
  P/0199/2022
• PIP number:
  EMEA-003187-PIP01-22
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Diagnosis of Alzheimer's disease
• Route(s) of administration:
  All routes of administration
• Contact for public enquiries:

  Eli Lilly and Co. Ltd.

  E-mail: [e-mail]

  Tel. [phone]

• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  21/06/2022

Decision

P/0199/2022 : EMA decision of 21 June 2022 on the granting of a product specific waiver for flortaucipir F18 (EMEA-003187-PIP01-22)

Reference Number: EMA/266265/2022